Back to Newsroom

Puma Biotechnology and Medison Pharma Enter into Exclusive Licensing Agreement to Commercialize NERLYNX® (neratinib) in Israel

LOS ANGELES–(BUSINESS WIRE)–Puma Biotechnology, Inc. (Nasdaq: PBYI), a biopharmaceutical company, and Medison Pharma Ltd, Israel’s leading commercial partner for innovative pharmaceuticals, have entered into an exclusive agreement under which Medison will commercialize NERLYNX® (neratinib) in Israel.